FDA Oversight of Cell Therapy Clinical Trials

被引：28

|

作者：

Au, Patrick ^{[1
]}

Hursh, Deborah A. ^{[1
]}

Lim, Agnes ^{[1
]}

Moos, Malcolm C., Jr. ^{[1
]}

Oh, Steven S. ^{[1
]}

Schneider, Bruce S. ^{[1
]}

Witten, Celia M. ^{[1
]}

机构：

[1] US FDA, Off Cellular Tissue & Gene Therapies, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA

来源：

SCIENCE TRANSLATIONAL MEDICINE | 2012年 / 4卷 / 149期

关键词：

D O I：

10.1126/scitranslmed.3004131

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

引用

收藏

页数：3

相关论文

共 50 条

[31] New clinical trials policy at FDA
Vastag, Brian
NATURE BIOTECHNOLOGY, 2006, 24 (09) : 1043 - 1043
[32] FDA pharmaceutical quality oversight
Yu, Lawrence X.
Woodcock, Janet
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 491 (1-2) : 2 - 7
[33] FDA tightens human oversight
Dove, A
NATURE MEDICINE, 2001, 7 (06) : 646 - 646
[34] The Case for Public Funding and Public Oversight of Clinical Trials
Lewis, Tracy R.
Reichman, Jerome H.
So, Anthony D.
ECONOMISTS VOICE, 2007, 4 (01):
[35] FDA to oversee reporting of clinical trials
Mark Ratner
Nature Biotechnology, 2012, 30 : 1163 - 1163
[36] New clinical trials policy at FDA
Brian Vastag
Nature Biotechnology, 2006, 24 : 1043 - 1043
[37] INSTITUTIONAL OVERSIGHT OF CLINICAL TRIALS AND THE DRUG APPROVAL PROCESS
Miller, Paul B.
OSGOODE HALL LAW JOURNAL, 2006, 44 (04): : 679 - +
[38] FDA tightens human oversight
Alan Dove
Nature Medicine, 2001, 7 : 646 - 646
[39] FDA to oversee reporting of clinical trials
Ratner, Mark
NATURE BIOTECHNOLOGY, 2012, 30 (12) : 1163 - 1163
[40] Biomarkers in T cell therapy clinical trials
Kalos, Michael
JOURNAL OF TRANSLATIONAL MEDICINE, 2011, 9

← 1 2 3 4 5 →